4BB.LSE 4BASEBIO UK SOCIETAS
- Market cap
- GBX 77.4M
- P/E
- -
- P/B
- 64.57x
- ROE
- -2,808.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is 4BB.LSE undervalued?
Graham numberThe Graham number of 4BASEBIO UK SOCIETAS cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
4BASEBIO UK SOCIETAS fundamental analysis
No fundamental analysis for 4BASEBIO UK SOCIETAS yet.
4BASEBIO UK SOCIETAS stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About 4BASEBIO UK SOCIETAS
4basebio PLC, together with its subsidiaries, engages in the research, development, manufacturing, and sale of synthetic DNA and RNA products in Europe, the United States, and internationally. It offers hpDNA, a double stranded linear DNA for viral and non-viral vector applications; opDNA, a partially opened, linear, double stranded DNA for in vitro transcription processes that produce mRNA for use in vaccines and therapeutics; oeDNA, a linear, double stranded DNA for genome…
Full company profile4BASEBIO UK SOCIETAS financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
4BASEBIO UK SOCIETAS annual financial statements
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 202K | 462K | 338K | 268K | 506K | 933K | 1.69M | 1.05M |
| Gross Profit | -28.0K | 274K | 269K | 239K | 340K | 630K | 548K | -1.53M |
| Operating Income | -420K | -622K | -3.53M | -5.84M | -8.05M | -12.0M | -16.7M | -35.8M |
| EBITDA | -169K | -345K | -3.21M | -5.41M | -7.34M | -11.0M | -15.6M | -33.5M |
| Net Income | -423K | -719K | -3.24M | -5.15M | -7.67M | -12.3M | -16.9M | -35.7M |
| EPS | -0.03 | -0.06 | -0.26 | -0.42 | -0.62 | -0.94 | -1.09 | -2.30 |
| Balance Sheet | ||||||||
| Total Assets | 1.16M | 17.8M | 14.7M | 11.7M | 11.9M | 44.7M | 29.5M | 27.1M |
| Total Liabilities | 3.05M | 2.35M | 3.01M | 4.57M | 12.4M | 18.3M | 19.4M | 25.8M |
| Shareholders' Equity | -1.89M | 15.5M | 11.7M | 7.12M | -492K | 26.4M | 10.1M | 1.27M |
| Cash & Short-term Investments | 80.0K | 15.0M | 9.59M | 4.35M | 3.07M | 34.6M | 17.8M | 14.1M |
| Total Debt | 2.59M | 1.72M | 1.76M | 3.35M | 10.5M | 15.2M | 16.5M | 23.1M |
| Cash Flow | ||||||||
| Operating Cash Flow | -269K | -1.02M | -2.74M | -4.70M | -6.18M | -10.7M | -14.8M | -33.0M |
| Capital Expenditure | 203K | 849K | 1.51M | 1.94M | 1.49M | 1.57M | 458K | 4.31M |
| Free Cash Flow | -472K | -1.87M | -4.25M | -6.65M | -7.67M | -12.3M | -15.2M | -37.3M |
| Ratios | ||||||||
| ROE | - | -4.7% | -27.7% | -72.3% | - | -46.8% | -167.2% | -2,808.5% |
| ROA | -36.6% | -4.0% | -22.0% | -44.1% | -64.3% | -27.6% | -57.2% | -131.6% |
| Net Profit Margin | -209.4% | -155.6% | -957.1% | -1,921.6% | -1,514.8% | -1,321.9% | -998.5% | -3,406.1% |
| Debt to Equity | - | 0.11x | 0.15x | 0.47x | - | 0.58x | 1.63x | 18.18x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
4BASEBIO UK SOCIETAS dividends
4BASEBIO UK SOCIETAS has not paid dividends in the last 7 fiscal years.
Who owns 4BASEBIO UK SOCIETAS
- Insiders 60.56%
- Institutions 14.17%
- Public & others 25.27%
- Shares outstanding 15.5M
- Free float 5.74M
4BASEBIO UK SOCIETAS company profile
- Company name
- 4BASEBIO UK SOCIETAS
- Ticker
- 4BB.LSE
- ISIN
- GB00BMCLYF79
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 140
- Fiscal year end
- December
- Address
- 25 Norman Way, Cambridge, United Kingdom, CB24 5QE
- Phone
- 44 1223 967 943
- Website
- 4basebio.com
About 4BASEBIO UK SOCIETAS
4basebio PLC, together with its subsidiaries, engages in the research, development, manufacturing, and sale of synthetic DNA and RNA products in Europe, the United States, and internationally. It offers hpDNA, a double stranded linear DNA for viral and non-viral vector applications; opDNA, a partially opened, linear, double stranded DNA for in vitro transcription processes that produce mRNA for use in vaccines and therapeutics; oeDNA, a linear, double stranded DNA for genome editing; osDNA, a DNA product that incorporates nucleotide modifications within the DNA backbone; and Hermes, a nanoparticle platform. The company also provides custom pegRNA and sgRNA manufacturing; and nanoparticle formulation services. Its products are used in mRNA vaccines and therapies, viral vectors, gene editing, DNA vaccines, and non-viral delivery applications. The company was formerly known as 4basebio UK Societas and changed its name to 4basebio PLC in July 2021. 4basebio PLC was founded in 2008 and is headquartered in Cambridge, the United Kingdom.
4BASEBIO UK SOCIETAS management
7- Dr. Manja Hermina Elisabeth Maria Boerman Ph.D.Executive Chair of the Board · born 1966
- Dr. Amy Jo WalkerCEO & Director · born 1993
- Dr. Heikki Lanckriet Ph.D.Founder, Technical Advisor & Non-Executive Director · born 1977
- Mr. Richard Edward Bungay A.C.A., B.Sc.Chief Financial Officer · born 1969
- Mr. Scott LorimerChief Operating Officer
- Ms. Jennifer GelmanVice President of Marketing
- Ms. Christine WolosinChief Commercial Officer